Clinical Trial Update: An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) [Phase 2]

View source ↗

Summary

Open-label extension study of palovarotene for Fibrodysplasia Ossificans Progressiva (Phase 2) with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Palovarotene (palovarotene)

Snippet

Sponsor: Clementia Pharmaceuticals Inc. | Conditions: Fibrodysplasia Ossificans Progressiva | Phase 2 | Status: COMPLETED | Results posted: 2024-05-17